JP2025521501A5 - - Google Patents
Info
- Publication number
- JP2025521501A5 JP2025521501A5 JP2024574565A JP2024574565A JP2025521501A5 JP 2025521501 A5 JP2025521501 A5 JP 2025521501A5 JP 2024574565 A JP2024574565 A JP 2024574565A JP 2024574565 A JP2024574565 A JP 2024574565A JP 2025521501 A5 JP2025521501 A5 JP 2025521501A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- approximately
- administered
- mosnetuzumab
- lenalidomide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263354491P | 2022-06-22 | 2022-06-22 | |
| US63/354,491 | 2022-06-22 | ||
| PCT/US2023/068804 WO2023250367A1 (en) | 2022-06-22 | 2023-06-21 | Methods for treatment of previously untreated follicular lymphoma with mosunetuzumab and lenalidomide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025521501A JP2025521501A (ja) | 2025-07-10 |
| JP2025521501A5 true JP2025521501A5 (enExample) | 2025-07-29 |
Family
ID=87519897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024574565A Pending JP2025521501A (ja) | 2022-06-22 | 2023-06-21 | モスネツズマブおよびレナリドミドによる、以前に処置されていない濾胞性リンパ腫の処置のための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240043553A1 (enExample) |
| EP (1) | EP4543546A1 (enExample) |
| JP (1) | JP2025521501A (enExample) |
| KR (1) | KR20250025678A (enExample) |
| CN (1) | CN119546334A (enExample) |
| AU (1) | AU2023286618A1 (enExample) |
| CA (1) | CA3259327A1 (enExample) |
| IL (1) | IL317679A (enExample) |
| MX (1) | MX2024015750A (enExample) |
| TW (1) | TWI881370B (enExample) |
| WO (1) | WO2023250367A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026009843A (ja) * | 2024-06-25 | 2026-01-21 | ジェネンテック， インコーポレイテッド | 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| CA3190376A1 (en) * | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma |
| JP7716473B2 (ja) * | 2020-11-04 | 2025-07-31 | ジェネンテック， インコーポレイテッド | 抗ｃｄ２０／抗ｃｄ３二重特異性抗体の皮下投薬 |
| TWI874719B (zh) * | 2020-11-04 | 2025-03-01 | 美商建南德克公司 | 用抗cd20/抗cd3雙特異性抗體進行治療之給藥 |
-
2023
- 2023-06-21 EP EP23748657.6A patent/EP4543546A1/en active Pending
- 2023-06-21 KR KR1020257000914A patent/KR20250025678A/ko active Pending
- 2023-06-21 CA CA3259327A patent/CA3259327A1/en active Pending
- 2023-06-21 JP JP2024574565A patent/JP2025521501A/ja active Pending
- 2023-06-21 CN CN202380047723.4A patent/CN119546334A/zh active Pending
- 2023-06-21 WO PCT/US2023/068804 patent/WO2023250367A1/en not_active Ceased
- 2023-06-21 TW TW112123338A patent/TWI881370B/zh active
- 2023-06-21 US US18/338,985 patent/US20240043553A1/en active Pending
- 2023-06-21 IL IL317679A patent/IL317679A/en unknown
- 2023-06-21 AU AU2023286618A patent/AU2023286618A1/en active Pending
-
2024
- 2024-12-17 MX MX2024015750A patent/MX2024015750A/es unknown